【摘要】 背景与目的:化疗是治疗晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的主要方法,但目前临床治疗效果不能令人满意。本研究的目的为比较NP方案和MVP方案治疗NSCLC的近期疗效和不良反应,为临床治疗提供指导。方法:48例Ⅲ～Ⅳ期NSCLC采用NP方案,即长春瑞滨(vinorelbine,NVB)25mg/m2d1,8及顺铂(cisplatin,DDP)35mg/m2d1～3联合化疗;62例Ⅲ～Ⅳ期NSCLC采用MVP方案,即丝裂霉素(mitomycin,MMC)6mg/m2d1、长春地辛(vindesine,VDS)3mg/m2d1,8及DDP30mg/m2d1～3联合化疗。结果:NP组CR和PR共24例,有效率50%,中位缓解期5.5个月,中位生存期11个月;MVP组CR和PR32例,有效率51.6%,中位缓解期6.5个月,中位生存期14.5个月,两组疗效无显著性差异(P>0.05)。结论:NP方案与MVP方案治疗晚期NSCLC疗效相近,不良反应可耐受。建议NP方案采用深静脉给药或改进给药方法,能较好地解决NVB所致的静脉炎。更多还原

【Abstract】 Background & Objective:Chemotherapy is the major treatment for advanced non small cell lung cancer(NSCLC). However,the efficacy is not satisfactory. From January 1996 to December 2000,two chemotherapy regimen [NP:vinorelbine(NVB)+cisplatin(DDP); MVP:mitomycin (MMC)+vindesine(VDS)+cisplatin] have been used to treat 110 advanced NSCLC patients. The response and major adverse reaction were analyzed and compared. Methods: Forty eight cases of advanced NSCLC (stage Ⅲ～Ⅳ) patients were treated with NP (NVB:25 mg/m2, d1,8;DDP:35 mg/m2, d1～3). The other 62 cases were treated with MVP regimen (MMC: 6 mg/m2,d1;VDS:3 mg/m2,d1,8;DDP:30 mg/m2 d1～3). Results: In NP group, the overall response rate was 50%(CR+PR=24);medium response time was 5.5 months; medium survival time was 11 months. In MVP group, the overall response rate was 51.6%(CR+PR=32), medium response time and survival time were 6.5 and 14.5 months, respectively. The major toxicities were myelosuppression and phlebitis in NP group,nausea/vomiting, myelosuppression in MVP group,respectively. Conclusion: NP and MVP regimen for advanced NSCLC have similar response rate (P >0.05). Deep vein injection and improved infusion can be used to prevent phlebitis in NP regimen.更多还原